On Tuesday, Shares of Morgan Stanley (NYSE:MS), added 1.67% and closed at $32.32 in the last trading session. MS stock opened its last trade at $32.25 and after floating in a range of $32.04 to $32.51. The company’s Market capitalization is $61.25 Billion with the total Outstanding Shares of 1.91 billion. During the 52-week trading session the minimum price at which share price traded, registered at $21.16 and reached to max level of $35.74. The Earnings per Share of the company stands at $2.18. Morgan Stanley (MS) recently stated net revenues of $8.9 billion for the third quarter ended September 30, 2016 contrast with $7.8 billion a year ago.4 For the current quarter, net income applicable to Morgan Stanley was $1.6 billion, or $0.81 per diluted share,5 contrast with income of $1.0 billion, or $0.48 per diluted share,5 for the same period a year ago.4
The prior year quarter included DVA revenues of $435 million. Apart From DVA in the prior year quarter, net revenues were $7.3 billion and income applicable to Morgan Stanley was $740 million, or $0.34 per diluted share.6
Compensation expense of $4.1 billion raised from $3.4 billion a year ago mainly driven by higher revenues. Non-compensation expenses of $2.4 billion reduced from $2.9 billion a year ago reflecting lower litigation costs and continued execution of the Firm’s expense administration programs.
The annualized return on average common equity was 8.7 percent in the current quarter.7
Institutional Securities net revenues were $4.6 billion reflecting strong performance across our sales and trading franchise, continued strength in M&A advisory and subdued underwriting.
Wealth Administration net revenues were $3.9 billion and pre-tax margin was 23%.3 Fee-based asset flows for the quarter were $13.5 billion.
Investment Administration stated net revenues of $552 million with assets under administration or supervision of $417 billion.
Shares of Array Biopharma Inc (NASDAQ:ARRY), lost -2.17% and closed at $6.31 in the last trading session. ARRY stock opened its last trade at $6.49 and after floating in a range of $6.18 to $6.53. The company’s Market capitalization is $1.00 Billion with the total Outstanding Shares of 162.09 million. During the 52-week trading session the minimum price at which share price traded, registered at $6.18 and reached to max level of $7.27. The Earnings per Share of the company stands at $-0.65. Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The companys drugs in Phase III clinical trials include Binimetinib, Encorafenib, and Selumetinib for the treatment of cancer, in addition to ASC08/Danoprevir, a protease inhibitor for hepatitis C virus. Its drug candidates in Phase II clinical trials comprise Filanesib, a kinesin spindle protein inhibitor for multiple myeloma; ARRY-797, a p38 inhibitor for Lamin A/C-related dilated cardiomyopathy; ASLAN001/Varlitinib, a pan-HER2 inhibitor for gastric or breast cancer; Ipatasertib/GDC-0068, an AKT inhibitor for cancer; Motolimod/VTX-2337, a toll-like receptor for cancer; Prexasertib/LY2606368, a chk-1 inhibitor for cancer; LOXO-101, a PanTrk inhibitor for cancer; and ONT-380/ARRY-380, an HER2 inhibitor for breast cancer.